40542 Federal Register / Vol. 87, No. 129 / Thursday, July 7, 2022 / Notices 

The meeting will be open to the 

public as indicated below. Individuals 

who plan to attend and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations should notify the 

Contact Person listed below in advance 

of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with thegrant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Regents of 

the National Library of Medicine. 

Date: September 13, 2022. 

Open: September 13, 2022, 10:00 a.m. to 

4:00 p.m. 

Agenda: Program Discussion. 

Place: Virtual Meeting. 

Closed: September 13, 2022, 4:00 p.m. to 

4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Contact Person: Christine Ireland, 

Committee Management Officer, Division of 

Extramural Programs, National Library of 

Medicine, 6705 Rockledge Drive, Suite 500, 

Bethesda, MD 20892, 301–594–4929, 

irelanc@mail.nih.gov. 

Any member of the public may submit 

written comments no later than 15 days in 

advance of the meeting. Any interested 

person may file written comments with the 

committee by forwarding the statement to the 

Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nlm.nih.gov/od/bor/bor.html where an 

agenda and any additional information for 

the meeting will be posted when available. 

This meeting will be broadcast to the public, 

and available for viewing at http://

videocast.nih.gov on September 13, 2022. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.879, Medical Library 

Assistance, National Institutes of Health, 

HHS). 

Dated: July 1, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–14476 Filed 7–6–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

preclinical development resources for 

potential new therapeutics for the 

treatment of cancer. The outcome of the 

evaluation will provide information to 

internal NCI committees that will 

decide whether NCI should support 

requests and make available contract 

resources for development of the 

potential therapeutic to improve the 

treatment of various forms of cancer. 

The research proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the 

proposed research projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; JUN2022 

Cycle 41 NExT SEP Committee Meeting. 

Date: August 4, 2022. 

Time: 9:00 a.m. to 3:00 p.m. 

Agenda: To evaluate the NCI Experimental 

Therapeutics Program Portfolio. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, Room 3A44, 

Bethesda, Maryland 20892 (WebEx Meeting). 

Contact Persons: Barbara Mroczkowski, 

Ph.D., Executive Secretary, Discovery 

Experimental Therapeutics Program, 

National Cancer Institute, NIH, 31 Center 

Drive, Room 3A44, Bethesda, Maryland 

20817, 301–496–4291, mroczkoskib@

mail.nih.gov. 

Toby Hecht, Ph.D., Executive Secretary, 

Development Experimental Therapeutics 

Program, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 3W110, 

Rockville, Maryland 20850, 240–276–5683, 

toby.hecht2@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: July 1, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–14440 Filed 7–6–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK SEP High 

Risk Multi-Center Clinical Study Cooperative 

Agreement U01 & U34. 

Date: July 28, 2022. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, 

NIDDK, 6707 Democracy Boulevard, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Cheryl Nordstrom, Ph.D., 

MPH, Scientific Review Officer, NIDDK/ 

Scientific Review Branch, National Institutes 

of Health, 6707 Democracy Blvd., Room 

7013, Bethesda, MD 20892, 301–402–6711, 

cheryl.nordstrom@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: July 1, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–14475 Filed 7–6–22; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES